Altamira Therapeutics Ltd.

NasdaqCM:CYTO Stock Report

Market Cap: US$3.2m

Altamira Therapeutics Management

Management criteria checks 2/4

Altamira Therapeutics' CEO is Thomas Meyer, appointed in Apr 2003, has a tenure of 21.08 years. total yearly compensation is CHF654.87K, comprised of 55.9% salary and 44.1% bonuses, including company stock and options. directly owns 0.89% of the company’s shares, worth $28.80K. The average tenure of the management team and the board of directors is 1.9 years and 4.8 years respectively.

Key information

Thomas Meyer

Chief executive officer

CHF654.9k

Total compensation

CEO salary percentage55.9%
CEO tenure21.1yrs
CEO ownership0.9%
Management average tenure1.9yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

Altamira Therapeutics completes enrollment in trial of its nasal spray to treat COVID

Sep 13

Altamira Therapeutics moving forward on plans to divest legacy assets, including Bentrio

Aug 30

Altamira starts development program for potential arthritis therapy

Jul 25

Altamira announces peer-reviewed publication on mRNA delivery platform

Jul 19

Altamira gains on peer-reviewed preclinical data publication for its RNA delivery platform

Jul 12

Auris Medical shares rise on OligoPhore Lymphoma study results

Jun 21

Auris Medical starts preparations for COVID-19 trial with Bentrio in India

Jun 01

Auris Medical updates on pollen challenge study for nasal spray

May 10

Are Insiders Buying Auris Medical Holding Ltd. (NASDAQ:EARS) Stock?

Dec 09
Are Insiders Buying Auris Medical Holding Ltd. (NASDAQ:EARS) Stock?

Auris Medical prices $8M direct equity offering, stock -22%

Dec 02

CEO Compensation Analysis

How has Thomas Meyer's remuneration changed compared to Altamira Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023CHF655kCHF366k

-CHF7m

Jun 30 2023n/an/a

-CHF24m

Mar 31 2023n/an/a

-CHF25m

Dec 31 2022CHF638kCHF366k

-CHF19m

Sep 30 2022n/an/a

-CHF23m

Jun 30 2022n/an/a

-CHF19m

Mar 31 2022n/an/a

-CHF18m

Dec 31 2021CHF1mCHF366k

-CHF7m

Sep 30 2021n/an/a

-CHF15m

Jun 30 2021n/an/a

-CHF12m

Mar 31 2021n/an/a

-CHF10m

Dec 31 2020CHF656kCHF364k

-CHF8m

Sep 30 2020n/an/a

-CHF7m

Jun 30 2020n/an/a

-CHF6m

Mar 31 2020n/an/a

-CHF6m

Dec 31 2019CHF586kCHF364k

-CHF7m

Sep 30 2019n/an/a

-CHF9m

Jun 30 2019n/an/a

-CHF10m

Mar 31 2019n/an/a

-CHF12m

Dec 31 2018CHF626kCHF364k

-CHF11m

Sep 30 2018n/an/a

-CHF12m

Jun 30 2018n/an/a

-CHF15m

Mar 31 2018n/an/a

-CHF18m

Dec 31 2017CHF552kCHF364k

-CHF24m

Compensation vs Market: Thomas's total compensation ($USD722.44K) is about average for companies of similar size in the US market ($USD661.49K).

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.

CEO

Thomas Meyer (55 yo)

21.1yrs

Tenure

CHF654,874

Compensation

Dr. Thomas Meyer, Ph.D. Founded Altamira Therapeutics Ltd. (formerly known as Auris Medical Holding Ltd.) (formerly known as Auris Medical Holding AG) in April 2003 and serves as Managing Director, Chairma...

Leadership Team

NamePositionTenureCompensationOwnership
Thomas Meyer
Founder21.1yrsCHF654.87k0.89%
CHF 28.8k
Marcel Gremaud
Chief Financial Officer2.5yrsno data0.0014%
CHF 46.1
Covadonga Paneda
Chief Operating Officer1.3yrsno datano data
Samuel Wickline
Chief Scientific Adviser1.3yrsno datano data

1.9yrs

Average Tenure

59.5yo

Average Age

Experienced Management: CYTO's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Thomas Meyer
Founder21.1yrsCHF654.87k0.89%
CHF 28.8k
Alain Munoz
Independent Non-Executive Director6.2yrsCHF49.91k0.012%
CHF 400.3
Mats Blom
Independent Non-Executive Director7.1yrsCHF49.91k0.012%
CHF 401.6
Wolfgang Arnold
Member of Tinnitus's Scientific Advisory Board4.8yrsno datano data
David Baguley
Member of Tinnitus's Scientific Advisory Board4.8yrsno datano data
Richard Salvi
Member of Tinnitus's Scientific Advisory Board4.8yrsno datano data
Hinrich Staecker
Member of Tinnitus's Scientific Advisory Board4.8yrsno datano data
Margrit Schwarz
Independent Director2.8yrsCHF49.91k0.0046%
CHF 148.4

4.8yrs

Average Tenure

58yo

Average Age

Experienced Board: CYTO's board of directors are considered experienced (4.8 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.